HSP90AA1 and melanoma: Clinical responses have been observed in patients with metastatic malignant melanoma treated with the HSP90 inhibitor 17-AAG (Banerji et al, 2008) and were associated with B-Raf and N-Ras mutations, leading to a phase II trial of the HSP90 inhibitor tanespimycin in patients with malignant melanoma, on which clinical activity has also been observed.